Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trialIacopo Olivotto, Amos Katz, Sara Saberi et al.|The Lancet|2020Cited by 1.2k
Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic CardiomyopathySara Saberi, Daniel Jacoby, Nuno Cardim et al.|Circulation|2020Cited by 234
B-RAF and its novel negative regulator reticulocalbin 1 (RCN1) modulates cardiomyocyte hypertrophyNadine Kramann, Tim Seidler|Cardiovascular Research|2014Cited by 19